Innovation in immuno-oncology: Leading companies in monoclonal antibody conjugates for cancer treatment

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,…

May 8, 2023 - 20:00
Innovation in immuno-oncology: Leading companies in monoclonal antibody conjugates for cancer treatment

The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Monoclonal antibody conjugates for cancer treatment.

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Monoclonal antibody conjugates for cancer treatment is a key innovation area in immuno-oncology

The primary purpose of antibody drug conjugates (ADCs) is to increase the efficacy of anticancer medications by minimising systemic drug distribution and targeting specific cells. ADC is a class of drug comprised of a monoclonal antibody conjugated to a cytotoxic drug through a chemical linker. To develop an effective ADC for cancer therapy, an appropriate target must be selected, a monoclonal antibody must be developed against the target, and then the antibody must be conjugated to cytotoxic agents to selectively deliver a toxic payload.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 90+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of monoclonal antibody conjugates for cancer treatment.

Key players in monoclonal antibody conjugates for cancer treatment – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to monoclonal antibody conjugates for cancer treatment

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
F. Hoffmann-La Roche 703 Unlock company profile
Daiichi Sankyo 293 Unlock company profile
AbbVie 259 Unlock company profile
Takeda Pharmaceutical 212 Unlock company profile
Philogen 197 Unlock company profile
Pfizer 192 Unlock company profile
Gilead Sciences 186 Unlock company profile
Seagen 168 Unlock company profile
Bristol-Myers Squibb 155 Unlock company profile
Amgen 154 Unlock company profile
Oxford BioTherapeutics 125 Unlock company profile
ImmunoGen 123 Unlock company profile
Stemcentrx 119 Unlock company profile
Astellas Pharma 110 Unlock company profile
Johnson & Johnson 95 Unlock company profile
GSK 85 Unlock company profile
Prothena 83 Unlock company profile
Bayer 76 Unlock company profile
Axon Neuroscience 68 Unlock company profile
Jiangsu Hengrui Medicine 54 Unlock company profile
BC Partners LLP 52 Unlock company profile
Sorrento Therapeutics 50 Unlock company profile
Siwa 49 Unlock company profile
Pierre Fabre Foundation 48 Unlock company profile
AstraZeneca 43 Unlock company profile
Neurimmune Holding 43 Unlock company profile
AC Immune 39 Unlock company profile
Ecole Polytechnique Federale de Lausanne 39 Unlock company profile
Sanofi 37 Unlock company profile
C. H. Boehringer Sohn 35 Unlock company profile
Mayo Clinic 35 Unlock company profile
Chiome Bioscience 34 Unlock company profile
City of Hope 30 Unlock company profile
Immunwork 28 Unlock company profile
Helix BioPharma 25 Unlock company profile
Shanghai Junshi Bioscience 25 Unlock company profile
Academia Sinica 24 Unlock company profile
U3 Pharma 24 Unlock company profile
United States Of America 23 Unlock company profile
TRON gGmbH 23 Unlock company profile
Thermo Fisher Scientific 23 Unlock company profile
A. Menarini Industrie Farmaceutiche Riunite 22 Unlock company profile
Oncomatryx Biopharma 22 Unlock company profile
Toray Industries 21 Unlock company profile
Asana BioSciences 20 Unlock company profile
Les Laboratoires Servier 20 Unlock company profile
MacroGenics 19 Unlock company profile
Aprogen pharmaceuticals 19 Unlock company profile
Regeneron Pharmaceuticals 19 Unlock company profile
Ministry of Trade and Industry, Singapore 19 Unlock company profile

Source: GlobalData Patent Analytics

F. Hoffmann-La Roche is the leading patent filer in monoclonal antibody conjugates for cancer treatment. F. Hoffmann-La Roche is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. Roche has multiple monoclonal antibody conjugates, some already approved, and some under development. Kadcyla, one of the two marketed drugs, is manufactured by Roche.

In terms of application diversity, AusHealth is the top company, followed by Epic Sciences and McSAF. By means of geographic reach, Astellas Pharma holds the top position, while TRON and Eisai stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow